Given that Onalespib is a known radiosensitizer64 and that it penetrates the BBB65 it would be tempting to evaluate its tumor suppressive effect along with standard irradiation in MYC-driven Group 3 patients where efficient treatment options are rare. Here, MYC is linked to neoplasm.